Candel Therapeutics partners with EVERSANA for potential US launch of CAN-2409 prostate cancer therapy

Candel Therapeutics, Inc.

Candel Therapeutics, Inc.

CADL

0.00
  • Candel Therapeutics entered product commercialization agreement with EVERSANA to support potential US launch of aglatimagene besadenovec (CAN-2409) in intermediate- to high-risk localized prostate cancer.
  • EVERSANA will provide integrated commercialization support spanning data and analytics, medical affairs, market access, plus field operations.
  • Deal aligns with planned biologics license application submission in Q4 2026.
  • IDEA Pharma remains engaged on path-to-market strategy and positioning for aglatimagene.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Candel Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604290805PRIMZONEFULLFEED9708940) on April 29, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.